drugset / Trial / NCT00863499
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
Non-randomizedParallel-groupOpen-labelHealth-services research
Summary
The aim of the iSPOT-A study is to: 1. identify brain, genetic and cognitive markers of Attention Deficit/Hyperactivity Disorder, and 2. identify brain, genetic and cognitive markers that predict treatment response to short-acting methylphenidate in children and adolescents diagnosed with Attention Deficit/Hyperactivity Disorder.
Timeline
- Start
- 2009-10
- Primary completion
- 2019-12
- Completion
- 2019-12
Publications
- Leikauf JE, Griffiths KR, Clarke SD, Kohn MR, Williams L. Attention-Deficit/Hyperactivity Disorder Subtypes Defined by Cognition Have a Distinct Neural and Clinical Profile and Differ in Response to Atomoxetine. J Am Acad Child Adolesc Psychiatry. 2026 May;65(5):697-711. doi: 10.1016/j.jaac.2025.07.007. Epub 2025 Jul 16.
- Arns M, Vollebregt MA, Palmer D, Spooner C, Gordon E, Kohn M, Clarke S, Elliott GR, Buitelaar JK. Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2018 Aug;28(8):881-891. doi: 10.1016/j.euroneuro.2018.06.002. Epub 2018 Jun 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methylphenidate | Small molecule | 5 mg | — |
| Comparator | Methylphenidate | Small molecule | 9 mg | — |